Çocuk Dergisi

GÖNDERBİLGİ
EnglishTürkçe

Derleme


DOI :10.5222/j.child.2019.06926   IUP :10.5222/j.child.2019.06926    Tam Metin (PDF)

Grup B Meningokok Enfeksiyonları ve Aşılama

Özge Kaba, Ayper Somer

Dünyanın heryerinde endemi ve epidemilere neden olan meningokokal enfeksiyonlar, saatler içerisinde mortalite ile sonuçlanan tablolara yol açabilir. Coğrafi özellikler, konak faktörü, mikroorganimanın serogrubu gibi faktörler seyri etkilemektedir. Edinilen sürveyans verilerine göre epidemilere en sık neden olan serogruplar A, B, C, W135 ve Y olarak belirlenmiştir. Bunun üzerine geliştirilen A, C, W135 ve Y serogruplarını içeren yeni meningokok aşıları ile tüm dünyada bu serogrupların görülme oranı belirgin olarak azalma göstermiştir. Ülkemizde ise bağışıklama programının Hib ve pnömokok aşılarının eklenmesiyle zenginleştirilmesinden sonra meningokokal hastalıklar çarpıcı bir şekilde kendini göstermiştir. Ön planda olduğu görülen serogrup B’ye karşı korunmanın yolları aranmış ve son dönemde ters vaksinoloji yöntemiyle serogrup B aşısı (4CMenB) geliştirilmiştir.

Anahtar Kelimeler: Meningokok B, invazif meningokokal hastalık, çocukluk çağı, aşılama
DOI :10.5222/j.child.2019.06926   IUP :10.5222/j.child.2019.06926    Tam Metin (PDF)

Group B Meningococcal Infections and Vaccination

Özge Kaba, Ayper Somer

Meningococcal infections leading to endemics and epidemics all over the world can lead to mortality resulting in hours. Factors such as geographical characteristics, host factors, serogroup of microorganism affect the course. According to the surveillance data, serogroups A, B, C, W135 and Y were the most common causes of epidemics. With the new meningococcal vaccines including serogroups A, C, W135 and Y, the incidence of these serogroups decreased significantly all over the world. In our country, meningococcal diseases have been striking after the immunization program has been enriched with the addition of Hib and pneumococcal vaccines. Protection against serogroup B, which appears to be in the forefront, has been sought and recently, serogroup B vaccine (4CMenB) has been developed by reverse vaccination method.

Anahtar Kelimeler: Meningococcus B, invazive meningococcal disease, childhood, vaccination

PDF Görünüm

Referanslar

  • 1. Pace D, Pollard AJ. Meningococcal disease: Clinical presentation and sequele. Vaccine 2012;305:3-9. https://doi.org/10.1016/j.vaccine.2011.12.062 google scholar
  • 2. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013 Sep 10;11(1):17. https://doi.org/10.1186/1478-7954-11-17 google scholar
  • 3. Muttalif AR, Presa JV, Haridy H, Gamil A, Serra LC, Cané A. Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events. Infect Dis Ther. 2019 Aug 30. https://doi.org/10.1007/s40121-019-00262-9 google scholar
  • 4. Vespa Presa J, Abalos MG, Sini de Almeida R, Cane A. Epidemiological burden of meningococcal disease in Latin America: A systematic literature review. Int J Infect Dis. 2019 Aug; 85:37-48. https://doi.org/10.1016/j.ijid.2019.05.006 google scholar
  • 5. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(5):317- 28. https://doi.org/10.1016/S1473-3099(10)70048-7 google scholar
  • 6. Centers for Disease Control and Prevention. Meningococcal home. Meningococcal disease in other countries. (Accessed November 12, 2019, available at https://www.cdc.gov/meningococcal/global.html). google scholar
  • 7. Adams DA, Thomas KR, Jajosky RA, Foster L, Sharp P, Onweh DH, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2014. MMWR Morb Mortal Wkly Rep 2016;63:1. https://doi.org/10.15585/mmwr.mm6354a1 google scholar
  • 8. Centers for Disease Control and Prevention. Meningococcal home. Surveillance.Surveillance Data Tables. (Accessed November 12, 2019, available at https://www.cdc.gov/meningococcal/surveillance/ surveillance-data.html#figure02) google scholar
  • 9. European Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA. Stockholm: ECDC; 2017. google scholar
  • 10. Ceyhan M, Yildirim I, Balmer P, Borrow R, Dikici B, Turgut M, et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis. 2008;14:1089-96. https://doi.org/10.3201/eid1407.070938 google scholar
  • 11. Ceyhan M, Ozsurekci Y, Gürler N, Karadag Oncel E, Camcioglu Y, Salman N, et al. Bacterial agents causing meningitis during 2013-2014 in Turkey:A multi-center hospital-based prospective surveillance study. Hum Vaccin Immunother 2016 Nov;12(11):2940-5. https://doi.org/10.1080/21645515.2016.1209278 google scholar
  • 12. Marshall GS, Dempsey AF, Srivastava A, Isturiz RE. US College Students Are at Increased Risk for Serogroup B Meningococcal Disease. J Pediatric Infect Dis Soc. 2019 May 11. pii: piz024. https://doi.org/10.1093/jpids/piz024 google scholar
  • 13. MacNeil JR, Blain AE, Wang X, Cohn AC. Current Epidemiology and Trends in Meningococcal DiseaseUnited States, 1996-2015. Clin Infect Dis. 2018;66(8):1276-81. https://doi.org/10.1093/cid/cix993 google scholar
  • 14. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. Invasive Meningococcal Disease. (Accessed November 12, 2019, available at: https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&FixDataset=1). google scholar
  • 15. European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019. google scholar
  • 16. World Health Organization. Health Topics. Meningitidis. Serogroup distribution of invasive meningococcal disease, 2018. (Accessed November 12, 2019, available at: https://www.who.int/emergencies/diseases/meningitis/serogroup-distribution-2018.pdf). google scholar
  • 17. Berkman E, Özben G. Meningococcic meningitis epidemic in Ankara. Mikrobiyol Bul. 1982;16:101-6. google scholar
  • 18. Berkman E, Özben G, İlhan O. A meningococcal epidemic in Ankara. Mikrobiyol Bul. 1977;11:256-66. google scholar
  • 19. Tuncer AM, Gür I, Ulya E. One daily ceftriaxone for meningococcemia and meningococcal meningitis. Pediatr Infect Dis J 1988; 7: 711-3. https://doi.org/10.1097/00006454-198810000-00009 google scholar
  • 20. Elmastas H, Narin N, Olcer N. Meningokoksemide epidemiyoloji. Klinik Pediatri 1992;1:58-61. google scholar
  • 21. Ceyhan M, Gürler N, Ozsurekci Y, Keser M, Aycan AE, Gurbuz V, et al. Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus pneumoniae during 2005-2012 in Turkey. A multicenter prospective surveillance study. Hum Vaccin Immunother. 2014;10(9):2706-12. https://doi.org/10.4161/hv.29678 google scholar
  • 22. T. C. Sağlık Bakanlığı. Meningokok Sürveyans Verileri, 2018 google scholar
  • 23. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2013;62:1-28. 122 Çocuk Dergisi 2019;19(3):116-123 google scholar
  • 24. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, Slack RC, Madeley RJ, Ait-Tahar K, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ 2000;320:846. https://doi.org/10.1136/bmj.320.7238.846 google scholar
  • 25. Ercis S, Köseoğlu O, Salmanzadeh-Ahrabi S, Ercis M, Akin L, Hasçelik C. The prevalence of nasopharyngeal Neisseria meningitidis carriage, serogroup distribution, and antibiotic resistance among healthy children in Cankaya municipality schools of Ankara province. Mikrobiyol Bul 2005;39:411-20. google scholar
  • 26. Gazi H, Surucuoglu S, Ozbakkaloglu B, Akcali S, Ozkutuk N, Degerli K, et al. Oropharyngeal carriage and penicillin resistance of Neisseria meningitidis in primary school children in Manisa, Turkey. Ann Acad Med Singapore 2004; 33:758-62. google scholar
  • 27. Tekin RT, Dinleyici EC, Ceyhan M, Karbuz A, Salman N, Sutçu M, et al. The prevalence, serogroup distribution and risk factors of meningococcal carriage in adolescents and young adults in Turkey. Hum Vaccin Immunother 2017 May 4;13(5):1182-9. https://doi.org/10.1080/21645515.2016.1268304 google scholar
  • 28. Çelebi S. Bakteriyel Menenjitte Epidemiyoloji, Korunma ve Meningokok Serogrup B Enfeksiyonu. J Pediatr Inf 2014; 8: 33-9. google scholar
  • 29. American Academy of Pediatrics. Meningococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: p.550-561. google scholar
  • 30. Robinson JL. Update on invasive meningococcal vaccination for Canadian children and youth. Paediatr Child Health. 2018 Feb;23(1):e1-e4. https://doi.org/10.1093/pch/pxx162 google scholar
  • 31. Centers for Disease Control and Prevention. Immunization Schedules. For Health Care Providers. Child and Adolescent Immunization Schedule(birth through 18 years) (Accessed November 12, 2019, available at: https://www.cdc.gov/vaccines/schedules/ hcp/imz/child-adolescent.html). google scholar
  • 32. European Centre for Disease Prevention and Control. Vaccine Scheduler. (Accessed November 12, 2019, available at: https://vaccine-schedule.ecdc.europa. eu/) google scholar
  • 33. Wilkins AL, Snape MD. Emerging clinical experience with vaccines against group B meningococcal disease. Vaccine 2018 Aug 28;36(36):5470-6. https://doi.org/10.1016/j.vaccine.2017.07.056 google scholar
  • 34. Pérez Rodríguez A, Dickinson Meneses F, Rodríguez Ortega M. Effectiveness of the anti-meningococcal vaccine VA-MENGO-BC in the first year of life of Cuban children, 1997-2008. Rev Cubana Med Trop 2011 MayAug;63(2):155-60. google scholar
  • 35. Harrison LH. Vaccines for prevention of group B meningococcal disease: Not your father’s vaccines. Vaccine 2015 Nov 27;33 Suppl 4:D32-8. https://doi.org/10.1016/j.vaccine.2015.05.101 google scholar
  • 36. Ladhani SN, Giuliani MM, Biolchi A, Pizza M, Beebeejaun K, Lucidarme J, Findlow J, Ramsay ME, Borrow R. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis 2016 Feb;22(2):309-11. https://doi.org/10.3201/eid2202.150369 google scholar
  • 37. De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, Boulianne N, Gagné H, Gilca V, Deceuninck G, Ouakki M, Skowronski DM. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine 2018 Dec 18;36(52):8039-46. https://doi.org/10.1016/j.vaccine.2018.10.095 google scholar
  • 38. European Medicines Agency. Medicines. Human medicine European public assessment report (EPAR):Bexsero. Product İnformation. (Accessed November 12, 2019, available at: https://www.ema.europa.eu/en/documents/product-information/bexsero-epar-productinformation_en.pdf). google scholar
  • 39. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013 Mar 9;381(9869):825-35. https://doi.org/10.1016/S0140-6736(12)61961-8 google scholar
  • 40. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012 Feb 8;307(6):573-82. https://doi.org/10.1001/jama.2012.85 google scholar
  • 41. Martinón-Torres F, Carmona Martinez A, Simkó R, Infante Marquez P, Arimany JL, Gimenez-Sanchez F, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial. J Infect. 2018 Mar;76(3):258-269. https://doi.org/10.1016/j.jinf.2017.12.005 google scholar
  • 42. Biolchi A, Tomei S, Santini L, Welsch JA, Toneatto D, Gaitatzis N, et al. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules. Hum Vaccin Immunother. 123 Ö. Kaba ve A. Somer, Grup B Meningokok Enfeksiyonları ve Aşılama 2019;15(3):725-31. https://doi.org/10.1080/21645515.2018.1537756 google scholar
  • 43. Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al. V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012 Feb 18;379(9816):617-24. https://doi.org/10.1016/S0140-6736(11)61713-3 google scholar
  • 44. Santolaya ME, O’Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013 Nov;9(11):2304-10. https://doi.org/10.4161/hv.25505 google scholar
  • 45. Prymula R, Esposito S, Zuccotti GV, Xie F, Barone M, Dull PM, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother. 2014;10(7):2005-14. https://doi.org/10.4161/hv.28666 google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Kaba, Ö., & Somer, A. (2019). Grup B Meningokok Enfeksiyonları ve Aşılama. Çocuk Dergisi, 19(3), 116-123. https://doi.org/10.5222/j.child.2019.06926


AMA

Kaba Ö, Somer A. Grup B Meningokok Enfeksiyonları ve Aşılama. Çocuk Dergisi. 2019;19(3):116-123. https://doi.org/10.5222/j.child.2019.06926


ABNT

Kaba, Ö.; Somer, A. Grup B Meningokok Enfeksiyonları ve Aşılama. Çocuk Dergisi, [Publisher Location], v. 19, n. 3, p. 116-123, 2019.


Chicago: Author-Date Style

Kaba, Özge, and Ayper Somer. 2019. “Grup B Meningokok Enfeksiyonları ve Aşılama.” Çocuk Dergisi 19, no. 3: 116-123. https://doi.org/10.5222/j.child.2019.06926


Chicago: Humanities Style

Kaba, Özge, and Ayper Somer. “Grup B Meningokok Enfeksiyonları ve Aşılama.” Çocuk Dergisi 19, no. 3 (Nov. 2024): 116-123. https://doi.org/10.5222/j.child.2019.06926


Harvard: Australian Style

Kaba, Ö & Somer, A 2019, 'Grup B Meningokok Enfeksiyonları ve Aşılama', Çocuk Dergisi, vol. 19, no. 3, pp. 116-123, viewed 15 Nov. 2024, https://doi.org/10.5222/j.child.2019.06926


Harvard: Author-Date Style

Kaba, Ö. and Somer, A. (2019) ‘Grup B Meningokok Enfeksiyonları ve Aşılama’, Çocuk Dergisi, 19(3), pp. 116-123. https://doi.org/10.5222/j.child.2019.06926 (15 Nov. 2024).


MLA

Kaba, Özge, and Ayper Somer. “Grup B Meningokok Enfeksiyonları ve Aşılama.” Çocuk Dergisi, vol. 19, no. 3, 2019, pp. 116-123. [Database Container], https://doi.org/10.5222/j.child.2019.06926


Vancouver

Kaba Ö, Somer A. Grup B Meningokok Enfeksiyonları ve Aşılama. Çocuk Dergisi [Internet]. 15 Nov. 2024 [cited 15 Nov. 2024];19(3):116-123. Available from: https://doi.org/10.5222/j.child.2019.06926 doi: 10.5222/j.child.2019.06926


ISNAD

Kaba, Özge - Somer, Ayper. “Grup B Meningokok Enfeksiyonları ve Aşılama”. Çocuk Dergisi 19/3 (Nov. 2024): 116-123. https://doi.org/10.5222/j.child.2019.06926



ZAMAN ÇİZELGESİ


Gönderim13.11.2019
Kabul19.11.2019
Çevrimiçi Yayınlanma05.12.2019

LİSANS


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.